

IAEA Symposium Secretariat:

Scientific Secretary: A. K. Padhy, IAEA
Conference Services: K. Morrison, IAEA
R. Perricos, IAEA
Administrative support: F.M. Wong, IAEA

Local Co-Ordination: O. Estrela Anselmi,
Santa Rita Hospital and
Sao Lucas Hospital

Location of the Symposium:

Centro de Eventos da PUCRS
(Pontifícia Universidade Católica
do Rio Grande do Sul)
Av. Ipiranga, 6681 - Building 41
Porto Alegre

Tel. No.: (55)(51) 33203566
Fax No.: (55)(51) 33203556

Working Language: English

Resolutions: No resolutions may be submitted for
consideration on any subject, no
votes will be taken.

TIMETABLE

Sunday, 18 January 2004

15:00–17:00 Registration

Monday, 19 January 2004

07:30 Registration
08:30–09:00 Opening Addresses
09:00–10:30 Session 1: Introductory Lectures
10:30–11:00 Tea/Coffee Break
11:00–13:00 Session 2: Instrumentation & Correlative Imaging
13:00–14:00 Lunch Break
14:00–15:45 Session 3: General Nuclear Oncology
15:45–16:00 Tea/Coffee Break
16:00–17:30 Session 4: Radiopharmaceuticals - I
19:00 Reception

Tuesday, 20 January 2004

08:30–10:30 Session 5: Radiopharmaceuticals - II, Dosimetry & Biology
10:30–11:00 Tea/Coffee Break
11:00–13:00 Session 6: Thyroid Cancer - I
13:00–14:00 Lunch Break
14:00–15:45 Session 7: Thyroid Cancer - II
15:45–16:00 Tea/Coffee Break
16:00–17:30 Session 8: Poster - I

Wednesday, 21 January 2004

08:30–10:30 Session 9: Radiopharmacy and Breast Cancer - I
10:30–11:00 Tea/Coffee Break
11:00–13:00 Session 10: Radiopharmacy and Breast Cancer - II
13:00–14:00 Lunch Break
14:00–15:45 Session 11: Neuroendocrine Tumours & General
15:45–16:00 Tea/Coffee Break
16:00–17:30 Session 12: Poster - II

Thursday, 22 January 2004

08:30–10:30 Session 13: Radioimmuno Detection & Therapy / Molecular Nuclear Medicine
10:30–11:00 Tea/Coffee Break
11:00–13:00 Session 14: Molecular Nuclear Medicine
13:00–14:00 Lunch Break
14:00–15:45 Session 15: Liver Cancer
15:45–16:00 Tea/Coffee Break
16:00–17:30 Session 16: Interactive Session

Friday, 23 January 2004

08:30–10:30 Session 17: Palliative Care & Other Therapies
10:30–11:00 Tea/Coffee Break
11:00–13:00 Session 18: Closing

SUNDAY, 18 JANUARY 2004

15:00–17:00 Registration

MONDAY, 19 JANUARY 2004

07:30 Registration

08:30–09:00 Opening Addresses

**09:00–10:30 SESSION 1:
INTRODUCTORY LECTURES**

**Chairpersons: W. Burkart, IAEA
E. Touya, Uruguay**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
--------------------------------------	----------------	--	-----------------------

Keynote Lectures:

77-IAEA-1	A.K. Padhy	IAEA	Programmatic activities of IAEA in nuclear medicine
191-UK-2	K.E. Britton	UK	Peptides, positrons, monoclonals and chemicals in cancer imaging and therapy
201-USA-1	H.D. Royal	SNM	Molecular imaging: What is it and what does it mean for the future of nuclear medicine

10:30–11:00 Tea/Coffee Break

**11:00–13:00 SESSION 2: INSTRUMENTATION &
CORRELATIVE IMAGING**

**Chairpersons: H.M. Abdel-Dayem, USA
E.N.P. Lima, Brazil**

Keynote Lectures:

210–USA-10	M.L. Goris	USA	PET and CT a review of post-hoc fusion compared to acquisition fusion (PET-CT)
------------	-------------------	-----	--

**11:00–13:00 SESSION 2 (cont'd): INSTRUMENTATION &
CORRELATIVE IMAGING**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
230-BEL-1	O. Van Der Borgh	Belgium	Introduction to medical cyclotron technology - application in PET
231-CRO-2	V. Simcic	Croatia	PET instrumentation - technical considerations

Two additional lectures: to be announced

13:00–14:00 Lunch Break

**14:00–15:45 SESSION 3:
GENERAL NUCLEAR ONCOLOGY**

**Chairpersons: A. Al-Nahhas, UK
 C.A. Buchpiguel, Brazil**

Keynote Lectures:

112-KUW-1	A.H. Elgazzar	Kuwait	Pathophysiologic basis of imaging bony metastases
153-ROK-3	J-K. Chung	WFNMB	Sodium iodide symporters: it's role in nuclear oncology

Contributed Papers:

8-ARG-6	S. Vazquez, et al	Argentina	SPECT with thallium or sestamibi in the differential diagnosis of brain lesions
9-ARG-7	S. Carpintiero, et al	Argentina	Central nervous system lesions, utility of MRI and SPECT fusion imaging
64-CZR-4	P. Koranda, et al	Czech Republic	99mTc-MIBI SPECT in the diagnosis of gliomas: Differences in the 99mTc-MIBI and 99mTc-DTPA accumulations in the lesions?
66-EGY-1	H. Moustafa, et al	Egypt	Different radionuclide imaging in diagnosis, assessment of response and detection of recurrence in bone & soft tissue tumours of the extremities
145-POL-1	E. Dziuk, et al	Poland	Somatostatin analog 99mTc-Depreotide and fusion imaging of single photon emission tomography (SPET) and computed tomography (CT) in the evaluation of solitary pulmonary nodules (SPN)

**14:00–15:45 SESSION 3 (cont'd):
GENERAL NUCLEAR ONCOLOGY**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
154-ROM-1	A.C. Chirion, et al	Romania	Bone metastasis in patients with paraneoplastic myasthenic syndrom - possible indication for bone scintigraphy
195-URU-1	O. Alonso, et al	Uruguay	Evaluation of occult lymph node metastases by means of ^{99m} Tc-MIBI scintigraphy and sentinel node biopsy with RT-PCR multi-marker assay in early-stage melanoma patients

15:45–16:00 Tea/Coffee Break

**16:00–17:30 SESSION 4:
RADIOPHARMACEUTICALS - I**

**Chairpersons: M.F. Barbosa, Brazil
 H. Vera Ruiz, Bolivia**

Keynote Lectures:

18-AUL-2	V. Kumar	Australia	Radiopharmacology of Re-188 DMSA(V)
24-BOL-1	H. Vera Ruiz	Bolivia	Cyclotrons in developing countries
232-ROK-5	S-M. Lim	Korea, Republic of	Introduction to KIRAMS-13: A cyclotron developed by Korea Institute of Radiological & Medical Sciences

Contributed Papers:

6-ARG-4	E. Obenaus, <i>et al</i> <i>Presented by:</i> S. Gomez de Castiglia	Argentina	In-111 and Y-90 labelled peptide radio-pharmaceuticals for diagnosis and therapy
27-BRA-2	B.L. Faintuch, et al	Brazil	Influence of ⁶⁷ Ga purity on the labeling of somatostatin analogs
28-BRA-4	E. Bortoleti de Araujo, et al	Brazil	Labeling of dotatate with ¹³¹ Iodine for therapy application
74-GRE-4	A. Nikolopoulou, et al	Greece	NTS1-R-Targeted diagnostic imaging of malignant tumors with ^{99m} Tc labeled neurotensin analogues
75-GRE-5	A. Nikolopoulou, et al	Greece	Comparative evaluation of ^{99m} Tc labelled bombesin analogues for targeting GRP-R-Positive neoplasms
80-IND-2	R. Krishnakumar, et al	India	Comparison of gallium-67 and Tc-99m tetrofosmin uptake in lymphoma

16:00–17:30

**SESSION 4 (cont'd):
RADIOPHARMACEUTICALS - I**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
85-IND-7	P.S. Choudhury, <i>et al</i>	India	99mTc-GHA: A promising agent for assessing tumour viability
19:00	Reception		

TUESDAY, 20 JANUARY 2004

08:30–10:30 **SESSION 5:
RADIOPHARMACEUTICALS - II,
DOSIMETRY & BIOLOGY**

Chairpersons: **S.J. Goldsmith, SNM
E.J. Garcia, Brazil**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
--------------------------------------	----------------	--	-----------------------

Keynote Lectures:

46-CAN-2	A.J. McEwan	SNM	Current concepts in the radiobiology of radioisotope therapy
227-USA-16	S. Borges-Neto	USA	ProstaScint and quadramet; prostate cancer staging and treatment with radionuclides
235-IND-30	B.A. Krishna	India	Evaluation of lymphoma patients using hybrid PET-CT imaging system

Contributed Papers:

5-ARG-3	M.C. Valdivieso, <i>et al</i> <i>Presented by:</i> M. Cabrejas	Argentina	Is dosimetry really necessary for differentiated thyroid cancer treatment?
30-BRA-6	J.A. Osso Jr. , <i>et al</i>	Brazil	Viability studies for the preparation of 188W-188Re generators at IPEN/CNEN-SP
82-IND-4	A. Bhattacharya , <i>et al</i>	India	Utility of 99mTc-GHA brain SPECT in the grading of brain tumors
96-IND-18	S. Banerjee , <i>et al</i>	India	¹⁷⁷ Lu-DOTMP, ¹⁵³ Sm-DOTMP, ¹⁷⁵ Yb-EDTMP and ¹⁸⁶ Re-CTMP: Novel agents for bone pain palliation and their comparison with ¹⁵³ Sm-EDTMP
132-PAK-2	A. Afshan , <i>et al</i>	Pakistan	Study on the synthesis, kit formulation and chemical kinetics of dissociation of ^{99m} Tc-labeled-PnAO-Biotin complex from avidin and streptavidin
163-SAU-1	I. Al-Jammaz , <i>et al</i>	Saudi Arabia	Fluorine-18 labeled bombesin peptide analog: A potential radiopharmaceutical for cancer detection by PET imaging
199-URU-5	H.S. Balter Binsky , <i>et al</i>	Uruguay	Radiolabelled DOTA-TATE: its evaluation for targeted radiotherapy

10:30–11:00 **Tea/Coffee Break**

11:00–13:00 **SESSION 6:
THYROID CANCER - I**

Chairpersons: **M. Marone, Brazil
I. Roca, Spain**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
<i>Keynote Lectures:</i>			
206-USA-6	S.J. Goldsmith	SNM	Management of thyroid cancer
190-UK-1 cancer	K.E. Britton	UK	A rational approach to the management of differentiated thyroid
202-USA-2	H.D. Royal	SNM	Radiation safety issues related to I-131 therapy
<i>Contributed Papers:</i>			
54-COL-3	L.M. Pabon Castilla, et al	Colombia	Correlation among calculated dose of I131 according to risk factors and post-therapy scans in patients with well differentiated thyroid cancer
57-CUB-2	A. Martinez R., <i>et al</i> <i>Presented by:</i> J.P. Oliva Gonzalez	Cuba	Treatment of differentiated thyroid cancer with low dose of 131-I
58-CYP-1	S. Frangos, et al	Cyprus	Thyroid carcinoma: The experience at the oncology center in Nicosia, Cyprus
59-CYP-2	O. Demetriadou, et al	Cyprus	Differentiated thyroid cancer treatment with I131: 9 years experience in Nicosia General Hospital
67-EST-1	E. Kelk, et al	Estonia	Recombinant human thyrotropin in postoperative management of metastatic differentiated thyroid carcinoma
142-PHI-2	E.A. Lim, <i>et al</i> <i>Presented by:</i> E.A. Barrenechea	Philippines	Significance of post-therapy whole body imaging with I-131 in well-differentiated thyroid cancer
180-THA-2	S. Sirisalipoch, et al	Thailand	Prospective randomized trial for the evaluation of the efficacy of low vs. high dose I-131 for post operative remnant ablation in differentiated thyroid cancer
186-TUR-2	D. Corapcioglu, <i>et al</i> <i>Presented by:</i> N.Ö. Küçük	Turkey	The role of scintigraphy after high dose treatment of differentiated thyroid cancer patients with negative I-131 whole body diagnostic scintigraphy and high serum TG level
13:00–14:00	Lunch Break		

14:00–15:45 **SESSION 7:
THYROID CANCER - II**

Chairpersons: **D. Howarth, Australia
B.A. Krishna, India**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
--------------------------------------	----------------	--	-----------------------

Keynote Lectures:

19-AUS-1	G. Riccabona, <i>et al</i> <i>Presented by:</i> M. Gabriel	Austria	What can therapy with Y-90-somatostatin-analogues achieve in patients with metastatic non-medullary carcinoma (NMTC) of the thyroid without I-131 uptake?
203-USA-3	H.D. Royal	SNM	Controversies related to I-131 therapy

Contributed Papers:

98-IND-20	S. Basu, et al	India	Performance of 18F-FDG PET in detecting non-iodine concentrating metastases from thyroid carcinoma at varying Tg levels: implications on sodium iodide symporter Tg, mRNA and GLUT receptor expression at various stages of differentiation in differentiated thyroid carcinoma
116-LIT-2	I. Kulakiene, et al	Lithuania	Thyroid cancer incidence in Lithuania over the period of 1978–2003
121-MEX-2	E. Avila Ramirez, et al	Mexico	Treatment of differentiated thyroid cancer with 131I in children: 23 years of experience
133-PAR-1	J.A. Jara Yorg, et al	Paraguay	Utility of serum thyroglobulin dosage and total body scan with 131Iodine for the evaluation and follow up of post operatory well differentiated thyroid carcinoma in Paraguay
225-YUG-6	J. Mihailovic, et al	Serbia and Montenegro	Survival of patients with locally invasive differentiated thyroid carcinoma treated with radioiodine

15:45–16:00 **Tea/Coffee Break**

16:00–17:30

SESSION 8:
POSTER - I

Chairpersons:

A. Belfer, Brazil
P. Bernal Trujillo, Colombia
A. Ellmann, South Africa
S. Frangos, Cyprus

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
4P-ARG-2	V.E. Soroa, et al	Argentina	Not only PET for oncological pathology
23P-BGD-4	M.A. Karim, et al	Bangladesh	24 years experience of management of differentiated thyroid carcinoma by radioiodine
31P-BRA-7	D. Grobocopatel, et al	Brazil	Pulmonary metastasis in osteosarcoma in bone scintigraphy: 2 case report
35P-BRA-11	S.M. Velasques de Oliveira, et al	Brazil	Diagnostic nuclear medicine in Brazil: Current status in five geographical regions
41P-BUL-2	T. Hadjieva, et al	Bulgaria	Carcinogenic risk after radioiodine ablation for early papillary thyroid cancer
42P-BUL-3	I. Kostadinova, et al	Bulgaria	Our first experience in the application of ⁸⁹ Sr and comparison of the results with those with ³² P in patients with bone metastases
43P-BUL-4	A. Klissarova, et al	Bulgaria	Bone marrow radioimmune scintigraphy in the assessment of breast cancer treatment
53P-COL-2	L.M. Pabon Castilla, et al	Colombia	Presence of positive antityroglobulin antibodies in patient with well differentiated thyroid cancer referred for therapy I131: Cases reports
60P-CYP-3	O. Demetriadou, et al	Cyprus	TC99m tetrofosmin in parathyroid imaging
61P-CZR-1	O. Kraft, et al	Czech Republic	Functionally active hepatic metastasis of the differentiated thyroid carcinoma
63P-CZR-3	K. Safarcik, et al	Czech Republic	The external quality assessment of tumor markers. Some problems of the preparation of control samples for PSA determination
76P-HUN-1	J. Szilvási, et al	Hungary	Nuclear medicine and MRI in differential diagnosis of doubtful spinal disorders
81P-IND-3	S.V. Solav, et al	India	Profile of osteolytic lesions on bone scan

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
87P-IND-9	D.K. Hazra, et al	India	Experimental studies on enhancing radioimmuno-localisation using reticulo-endothelial system blockade
88P-IND-10	S. Ray, et al	India	A simple early soft tissue phase image while performing a routine 99mTc-MDP bone scan can serve the purpose of a screening mammography in early detection of breast cancer
90P-IND-12	P.S. Soni, et al	India	Design of colon targeting drug delivery systems using natural polymeric carriers and their evaluation by gamma scintigraphy technique
92P-IND-14	B.K. Das, et al	India	Does follicular carcinoma of thyroid from endemic region behave more aggressively?
93P-IND-15	R. Kumar, et al	India	Can Tc-99m tetrofosmin/ sestamibi lung scintigraphy differentiate malignant from benign lung masses?
102P-IND-24	S. Basu, et al	India	Thyroid carcinoma: Unusual pathologies and presentations
104P-IND-26	D.K. Hazra, et al	India	Clinical experience with gammaglo bulins in enhancing radiobioconjugate targetting by reticuloendothelial system blockade
106P-IRA-1	F. Saddadi, et al	Iran, Islamic Republic of	Role of 99mTc-labeled RBC SPECT in hemangioma of the liver
107P-IRA-2	F. Saddadi, et al	Iran, Islamic Republic of	Doubled-phase Tc99m-sestamibi imaging in localization of abnormal parathyroid glands
119P-MAK-2	A. Ugrinska, et al	The Frmr.Yug. Republic of Macedonia	Abstract databases in nuclear medicine: New database for articles not indexed in PubMed
126P-MOR-1	N. Ben Raïs Auoad, et al	Morocco	Following up and efficiency of 131 iodine therapy in differentiated thyroid carcinoma (excluding medullar) -Moroccan situation-
127P-MOR-2	N. Ben Raïs Auoad, et al	Morocco	African situation in thyroid cancer
135P-PAR-3	J.A. Jara Yorg, et al	Paraguay	Well differentiated thyroid carcinoma. Treatment with 131I and its follow up in Paraguay
141P-PHI-1	J.M. Obaldo, et al	Philippines	Value of 201Tl imaging in predicitng therapeutic 131I uptake in patients with thyroglobulin-positive but 131I scan-negative differentiated thyroid cancer

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
150P-POL-6	P. Zorga, et al	Poland	The effectiveness of strontium-89 in metastatic bone pain palliative treatment
152P-ROK-2	W. Choe, et al	Korea, Republic of	A role of skeletal scintigraphy in nuclear oncology at a medium-sized hospital in South Korea
155P-ROM-2	I. Codorean, et al	Romania	Treatment of metastatic bone pain — experience in Romania
157P-RUS-1	A.F. Tsyb, et al <i>Presented by:</i> P.I. Garbuzov	Russian Federation	Radionuclide therapy in Russia. Experience, problems and perspectives
158P-SAF-1	A.C. Otto, et al	South Africa	Early experience with 99mTc sestamibi uptake in bronchial carcinoma
161P-SAF-4	M.D.T.H. Vangu, et al	South Africa	Clinical presentation and outcome in patients treated for papillary and follicular carcinoma of the thyroid: patterns in Johannesburg
162P-SAF-5	S.M. de Canha, et al	South Africa	Use of 131I-MIBG: Tygerberg experience
166P-SLK-2	R. Hajts, et al	Slovakia	Our experience with nuclear medicine methods in the follow-up patients with thyroid cancer
168P-SLK-4	M. Vereb, et al	Slovakia	Radiogated surgery: First experiences with surgical gamma probe
173P-SPA-1	O. Caballero Carpena, et al	Spain	Problems and complications in treatment with radioiodine in patients with differentiated thyroid cancer
175P-SRL-1	R.S. Jayatilake, et al	Sri Lanka	Results of treatment of differentiated thyroid cancers using I131 at Sri Lanka's first private institution
176P-SRL-2	L. Watawana, et al	Sri Lanka	Experimental radioimmunotargetting: Gold, iodine and technetium as labels
178P-SYR-3	M. Zein, et al	Syrian Arab Republic	Clinical results of 89Sr-chloride application for treatment of bone metastasis

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
181P-TUN-1	H. Hammami, et al	Tunisia	Iodine-131 therapy in differentiated thyroid cancer
182P-TUN-2	S. Boughattas, et al	Tunisia	Impact of chronic lymphocytic thyroiditis coexisting with differentiated thyroid cancer on the effectiveness of remnants ablation
183P-TUN-3	S. Boughattas, et al	Tunisia	Impact of chronic lymphocytic thyroiditis on the prognosis of differentiated thyroid cancer
184P-TUN-4	S. Boughattas, et al	Tunisia	Scintigraphic visualization of distant metastases from differentiated thyroid cancer prior to thyroidectomy
187P-TUR-3	N.Ö. Küçük, et al	Turkey	Detection of sentinel lymph node with lymphoscintigraphy and surgical gamma probe in head and neck cancer
189P-UKR-2	N. Afanasieva, et al <i>Presented by:</i> N. Pilipenko	Ukraine	The use of 131I-metaiodine benzylguanidine (131I-MIBG) in medullary carcinoma of the thyroid gland treatment
198P-URU-4	G. Lago, et al	Uruguay	Protocol for treatment and follow-up of differentiated thyroid carcinoma
200P-URU-6	A.F. García Texeira, et al	Uruguay	Determination of effective half-life from 131-I in the therapy of a patient under dialysis treatment
216P-UZB-1	S.I. Ismailov, et al	Uzbekistan	Early diagnostics and treatment of thyroid carcinoma
218P-VIE-2	Trinh Thi Minh Chau, et al	Viet Nam	Thyroglobulin and metastases after thyroidectomy in differentiated thyroid cancer
222P-YUG-3	V. Artiko, et al	Serbia and Montenegro	The role of immunoscintigraphy in the detection of colorectal carcinomas
228P-IND-28	S. Basu, et al	India	Effect of low dose 131I-MIBG therapy in metastatic neural crest tumours: evaluation by recist and quality of life questionnaire

WEDNESDAY, 21 JANUARY 2004

08:30–10:30 **SESSION 9:
RADIOPHARMACY and BREAST CANCER - I**

Chairpersons: **B. Birkenfeld, Poland
J. Buscombe, UK**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
<i>Keynote Lectures:</i>			
211-USA-11	S. Srivastava	USA	Current trends in therapeutic radiopharmaceuticals
172-SLO-4	M. Snoj	Slovenia	Application of surgical gamma-probe in surgical oncology
229-ROK-4	M-C. Lee	WFNMB	PET in the management of breast cancer
<i>Contributed Papers:</i>			
3-ARG-1	M.H. Velazquez Espeche, et al	Argentina	Sentinel lymph node in breast cancer using a radiocolloid particle produced in Argentina
32-BRA-8	C.E. Anselmi, et al	Brazil	Prognostic value of the 99mTc-Isonitrile washout rate in neoadjuvant chemotherapy in patients with locally advanced breast cancer
55-CRO-1	M. Lacic, et al	Croatia	Mammoscintigraphy in evaluation of the patients with breast disorders
83-IND-5	P.S. Choudhury, et al	India	Indegenous surgical gamma probe: performance evaluation in the detection of sentinel node in breast cancer: A preliminary report
120-MEX-1	E.G.N.García, et al	Mexico	Follow up of breast cancer by bone scintigraphy
197-URU-3	G. Lago, et al	Uruguay	Radioguided sentinel node biopsy with 99mTc colloidal (Re) sulphide: Our experience
10:30–11:00	Tea/Coffee Break		

11:00–13:00 **SESSION 10:
RADIOPHARMACY and BREAST CANCER - II**

Chairpersons: **P.A. Filho, Brazil**
 V. Obradovic, Serbia and Montenegro

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
<i>Keynote Lectures:</i>			
17-AUL-1	D. Howarth	Australia	Evolving role of scinti-mammography in breast cancer
204-USA-4	C.R. Divgi	SNM	Treatment response in oncology
<i>Contributed Papers:</i>			
7-ARG-5	H. García del Río, <i>et al</i> <i>Presented by:</i> M. del C. Alak	Argentina	Radionuclide localization of sentinel lymph node (SLN); our experience in 14 years
25-BOH-1	Z. Rajkova, et al	Bosnia and Herzegovina	Scintimammography with 99mTc sestamibi in breast cancer
26-BRA-1	B.G. Viterbo de Oliveira, et al	Brazil	Sestamibi[99mTc] uptake on scintimammography: the influence of histologic grading in the detection of breast carcinoma
37-BRA-13	G. Junqueira Jr., et al	Brazil	Sentinel lymph node mapping and biopsy for melanoma in South Brazil
40-BUL-1	E. Piperkova, et al	Bulgaria	99m-Techneium tetrofosmin and 99m-Tc methylene diphosphonate in pre-surgical breast cancer
44-BUL-5	S.B. Sergieva, et al	Bulgaria	99mTc-MIBI scintigraphy as a functional method for multi drug resistance (MDR) evaluation in breast cancer patients
62-CZR-2	O. Kraft, et al	Czech Republic	Detection of sentinel lymph node in breast cancer and malignant melanoma-Influence of some factors on detection success rate
73-GRE-3	D. Kyriaki, et al	Greece	Sentinel lymph node (SLN) detection changes the biopsy sites in melanoma patients. Our experience
84-IND-6	P.S. Choudhury, et al	India	Role of scintimammography in post surgical management of breast cancer
94-IND-16	R. Kumar, et al	India	Comparison of FDG-PET and sentinel lymph node (SLN) biopsy in the detection of axillary lymph node metastases in early breast cancer patients
131-PAK-1	N.A. Laghari, et al	Pakistan	Role of 99mTc-MIBI in evaluation of palpable breast lesions

11:00–13:00 **SESSION 10 (cont'd):**
RADIOPHARMACY and BREAST CANCER - II

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
179-THA-1	S. Namwongprom, <i>et al</i>	Thailand	Breast lymphoscintigraphy for sentinel node identification in clinically axillary node negative breast cancer: A preliminary report of 35 cases

13:00–14:00 **Lunch Break**

14:00–15:45 **SESSION 11:**
NEUROENDOCRINE TUMOURS
& GENERAL

Chairpersons: **H. Amaral, Chile**
J.C. Meneghetti, Brazil

Keynote Lectures:

174-SPA-2	I. Roca	Spain	Current trends in paediatric oncology
192-UK-3	J. Buscombe	UK	Radionuclide treatment of neuroendocrine tumours
234-URU-7	F. Mut Bastos	Uruguay	Cardiac effects of chemo-radiotherapy and current protocols for cardiac monitoring before and during cancer therapy

Contributed Papers:

13-ARG-11	M.S. Racioppi, <i>et al</i>	Argentina	Predictive value of Tc99m-Sestamibi scintigraphy in the assessment of neoadjuvant chemotherapy response in patients with high grade sarcomas
34-BRA-10	A.A.R. Chaves, <i>et al</i>	Brazil	Thallium-201 (TL) and sestamibi-99mTc (MB) SPECT in patients with central nervous system (CNS) lesions
56-CUB-1	Y. Peña Quian, <i>et al</i>	Cuba	Role of scintigammagraphy with 99mTc-gluthatione and 99m-Tc-MIBI in the evaluation and staging of lymphoma
71-GRE-1	T. Spyridonidis, <i>et al</i>	Greece	Prediction of response to first-line chemotherapy with sestamibi imaging, in lymphoma patients. A preliminary report.
72-GRE-2	D. Kryiaki, <i>et al</i>	Greece	Chromogranin-A: A specific tumor marker for the follow up of patients with metastatic carcinoid tumors. Comparison of different neuroendocrine tumor markers
79-IND-1	R. Krishnakumar, <i>et al</i>	India	Assessment of response of limb sarcoma to neoadjuvant chemotherapy with Tc99m sesta MIBI

14:00–15:45 **SESSION 11 (cont'd):
NEUROENDOCRINE TUMOURS
& GENERAL**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
185-TUR-1	N.Ö. Küçük, et al	Turkey	Tc-99m MIBI SPECT for the evaluation of response to therapy in brain tumors – preliminary results
220-YUG-1	V. Obradovic, et al	Serbia and Montenegro	Detection of nasopharyngeal carcinomas by thallium-201 and technetium-99m sestamibi SPECT
15:45–16:00	Tea/Coffee Break		
16:00–17:30	SESSION 12: POSTER - II		
Chairpersons:	O. Demetriadou, Cyprus J.A. Jara Yorg, Paraguay E. Barrenechea, Philippines V.E. Soroa, Argentina		
10P-ARG-8	E.P. Parma, et al	Argentina	Radiolabelled peptides: Diagnosis, treatment and response evaluation
14P-ARG-12	M.S. Racioppi, et al	Argentina	Utility of Tc99m-Sestamibi scintigraphy in the post surgical assessment as a predictor of recurrences in patients with osteosarcomas
15P-ARG-13	E.C. Noguera, et al	Argentina	99mTc-Cistine-Glucosamine in the evaluation of oncologic patients
16P-ARM-1	N. Hovhannisyany, <i>et al</i> <i>Presented by:</i> G. Khachatryan	Armenia	Breast cancer: Development of algorithms on the diagnostic process and prospective treatment control
20P-BGD-1	F. Alam, et al	Bangladesh	Iodine-131 scintiscan and serum thyroglobulin level both are least dependable in detection of lymph node metastasis
21P-BGD-2	A.H. Jehan, et al	Bangladesh	Role of nuclear techniques in oncological practice in Bangladesh
33P-BRA-9	T. Watanabe, et al	Brazil	Influence of hormonal replacement with thyroxine in diagnostic evaluation of thyroid carcinoma with FDG using a dual head coincidence camera
36P-BRA-12	L.S. Machado, et al	Brazil	The role of technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
39P-BRA-15	G. Junqueira Jr., et al	Brazil	Sentinel lymph node biopsy in local recurrence of cutaneous melanoma

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
48P-CPR-1	S. Chen, et al	China	Sentinel lymph nodes lymphoscintigraphy and biopsy in breast cancer
49P-CPR-2	Y. Dang, et al	China	FDG uptake in the fatty tissues of supraclavicular and the vascular structure of the lung hilum
51P-CPR-4	Y. Dang, et al	China	Clinical application of PET/CT imaging in search of the primary carcinoma
68P-EST-2	S. Nazarenko, et al	Estonia	Clinical value of FDG-PET in cutaneous malignant melanoma: First experience in Estonia
86P-IND-8	U. Ravishankar, et al	India	Treatment of thyroid cancer with I-131 in a private setup-our 5 year experience
100P-IND-22	S. Basu, et al	India	2-[F-18] FDG PET in uncommon malignancies
101P-IND-23	S. Basu, et al	India	18F-FDG PET in the clinical decision making of lymphoma patients: Staging and prognostication, evaluating treatment response and residual disease and detecting preclinical relapse
109P-IRA-4	M. Moharamzadeh, et al	Iran, Islamic Republic of	Development of tPSA kit in detection and evaluation of prostate cancer in I.R. of Iran with assistance of IAEA technical co-operation
111P-JPN-1	N. Watanabe, et al	Japan	Effect of auger electrons internalized as indium-111-labeled N-MYC phosphorothioate antisense oligonucleotide (IN-111-N-MYC-AS) on human neuroblastoma cells – in vitro and in vivo studies
113P-LAT-1	J. Eglitis, et al	Latvia	Technological evolution of axillary lymphnodes radiological visualisation in breast cancer patients
114P-LEB-1	A. El Ezzi, et al	Lebanon	In vitro radioimmunoassay of prostate - specific antigen (PSA) for the screening and management of prostate cancer in Lebanon
115P-LIT-1	N. Jurkiene, et al	Lithuania	First experience of brain tumour scintigraphy with 99mTc-MIBI before and after surgery
117P-LIT-3	S. Tiskevicius, et al	Lithuania	Does breast radiographic appearance influence success of sentinel lymph node biopsy
118P-MAK-1	A. Ugrinska, et al	The Frmr.Yug. Republic of Macedonia	Tumor markers and bone scan in breast cancer patients

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
122P-MLI-1	S. Sidibé, et al	Mali	Hepatitis B virus and primary liver carcinoma in Mali
123P-MLT-1	A. Samuel, et al	Malta	Feasibility of performing I123 MIBG scintigraphy in patients with neuroblastoma in the Maltese islands
124P-MLT-2	R. Desai, et al	Malta	The ionising radiation (medical exposure) regulations - IR (ME) R, Malta
128P-NAM-1	K.S. von Wenzel-Obholzer, et al	Namibia	Nuclear oncology in a developing country: Namibia
136P-PER-1	G. Mendoza, et al	Peru	Correlation between PSA, bone scan and gleason score in patients with prostate cancer
137P-PER-2	R.E. Morales, et al	Peru	Intraoperative lymphatic mapping with Dextran Tc 99m and blud dye for sentinel node detection in patients with primary vulvar malignancies
138P-PER-3	P. Saavedra, et al	Peru	Ablation with iodine 131 in thirteen children and adolescents with differentiated cancer thyroid
139P-PER-4	R.E. Morales, et al	Peru	Intraoperative lymphatic mapping with Dextran Tc 99m and blud dye for sentinel node detection in patients with primary vulva following radiotherapy for cervical carcinoma
144P-PHI-4	C.C. Deocarís, et al	Philippines	Tumor suppressor p53 biology, its role in radioresponse and the analysis of p53 mutation/expression among Filipino breast cancers
146P-POL-2	A. Plachcinska, et al	Poland	Usefulness of receptor scintigraphy using 99mTc-EDDA/HYNIC-TOD in differential diagnostics of solitary pulmonary nodules
147P-POL-3	M. Bilski, et al	Poland	Use of the 131I-labeled monoclonal anti-β3 antibody for diagnosis of tumor neoangiogenesis
148P-POL-4	A. Hubalewska, et al	Poland	Preliminary clinical evaluation of somatostatin receptor scintigraphy (SRS) with 99mTc-EDDA/HYNIC-TATE in comparison to 111In-Octreoscan and 131I MIBG scans
149P-POL-5	T. Budlewski, et al	Poland	The usefulness of 131I-MIBG scintigraphy in assessing the staging of neuroectodermal tumors in children – our experience
156P-ROM-3	M. Gherghe, et al	Romania	The 99mTc MDP three phase bone scintigraphy in the evaluation of malignant bone and soft tissue tumors

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
159P-SAF-2	A.C. Otto, et al	South Africa	The evaluation of breast carcinoma with 99mTc sestamibi mammography
160P-SAF-3	A. Ellmann, et al	South Africa	Solitary pulmonary nodules: Tc-99m MIBI can discriminate between malignant and benign lesions in a region with a high prevalence of tuberculosis
165P-SLK-1	P. Koranda, et al <i>Presented by:</i> L. Kaliska	Slovakia	Efficacy of sentinel lymph node biopsy in patients with malignant melanoma using lymphoscintigraphy and intraoperative blue dye lymphatic mapping
167P-SLK-3	J. Lepej, et al	Slovakia	Availability of oncological nuclear medicine in the regions of Slovakia
169P-SLO-1	J. Fettich, et al	Slovenia	Production and clinical Evaluation of 99M-Tc-octreotide
170P-SLO-2	J. Fettich, et al	Slovenia	Evaluation of 4 methods to localise parathyroid adenoma using 99m-Tc-MIBI
171P-SLO-3	V. Fidler, et al	Slovenia	Development of new gamma camera localization method for sentinel nodes by image fusion and navigation in lymphoscintigraphy
188P-UKR-1	N. Pilipenko, et al	Ukraine	Radionuclide diagnosis of hemopoiesis disorders in cancer patients
196P-URU-2	J. Gaudiano, et al	Uruguay	Usefulness of radioguided surgery in osteoid osteoma
217P-VIE-1	Tran Xuan Truong, et al	Viet Nam	Measurement of some tumour markers by IRMA in Vietnam
221P-YUG-2	D. Sobic-Saranovic, et al	Serbia and Montenegro	Use of 99mTc-MIBI and 201TI scintigraphy in evaluation of tumor necrosis in lung cancer
223P-YUG-4	J. Vojcic, et al	Serbia and Montenegro	Noticeable rise in incidence of hurthle cell carcinoma – are we paying the Chernobil toll?
224P-YUG-5	L. Jaukovic, et al	Serbia and Montenegro	Role of 99mTc-tetrofosmin scintimammography in diagnosis of breast cancer patients

THURSDAY, 22 JANUARY 2004

08:30–10:30 **SESSION 13:
RADIOIMMUNO DETECTION & THERAPY /
MOLECULAR NUCLEAR MEDICINE**

Chairpersons: **A. Alavi, USA
A.J. McEwan, SNM**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
--------------------------------------	----------------	--	-----------------------

Keynote Lectures:

129-NET-1	F.H.M. Corstens	EANM	Radionuclide treatment of non-hodgkin's lymphoma
194-UK-5	A. Al-Nahhas	UK	Use of PET in cancer thyroid
209-USA-9	M. L. Goris	USA	Treating low grad non-hodgkin's lymphoma with radiolabeled anti-CD20
213-USA-13	G. Wiseman	USA	Radionuclide therapy of non-hodgkin's lymphoma

Contributed Papers:

97-IND-19	S. Basu, et al	India	The role of whole body PET with 2-[F-18] FDG in medullary carcinoma thyroid (MCT)
110-ISR-1	I. Garty, et al	Israel	Radioimmunoscinigraphy: General review, self experience and some "tips" for beneficial use and correct interpretation
226-SWE-1	J. Elgqvist	Sweden	Radioimmunotherapy of intraperitoneally growing NIH:OVCAR-3 cells in nude mice with 211At conjugated monoclonal antibody MX35

10:30–11:00 **Tea/Coffee Break**

11:00–13:00 **SESSION 14:
MOLECULAR NUCLEAR MEDICINE**

Chairpersons: **F.H.M. Corstens, EANM
H.D. Royal, SNM**

Keynote Lectures:

214-USA-14	H. Abdel-Dayem	USA	New challenges in PET imaging
215-USA-15	A. Alavi	USA	Functional and metabolic imaging of brain tumours

11:00–13:00 **SESSION 14 (cont'd):**
MOLECULAR NUCLEAR MEDICINE

<i>No. of Paper</i> <i>IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member</i> <i>State/Organization</i>	<i>Title of Paper</i>
--	----------------	--	-----------------------

Contributed Papers:

12-ARG-10	M.S. Racioppi, et al	Argentina	Efficiency of PET/CT in the selection of biopsy sites. Presentation of two clinical cases
29-BRA-5	S. Dragosavac, et al	Brazil	18F-FDG images of a gastro-intestinal stromal tumor performed before and after treatment
47-CHI-1	T. Massardo Vega, et al	Chile	Experience with PET FDG: Preliminary analysis
50-CPR-3	Y. Dang, et al	China	The clinical value of PET/CT in diagnosis and management of the lung nodule
99-IND-21	S. Basu, et al	India	2-[F-18] FDG PET in the clinical decision making of esophageal carcinoma: Initial staging and restaging, evaluating treatment response and residual disease and detecting relapse
143-PHI-3	F.G.M. Estrada, et al <i>Presented by:</i> E.A. Barrenechea	Philippines	PET in oncology: The Philippine setting
151-ROK-1	S-E. Kim, et al	Korea, Republic of	Intraindividual comparison of F-18-FLT PET and F-18 FET PET in brain tumor patients

13:00–14:00 **Lunch Break**

14:00–15:45 **SESSION 15:**
LIVER CANCER

Chairpersons: **C.R. Divgi, SNM**
 F.X. Sundram, Singapore

Keynote Lectures:

78-IAEA-2	A.K. Padhy	IAEA	IAEA initiatives in liver cancer
236-USA-17	F.F. (Russ) Knapp, Jr.	USA	Rhenium Radio-pharmaceuticals for therapy of oncological disorders
193-UK-4	J. Buscombe	UK	Treatment of HCC with I-131 lipiodol

**14:00–15:45 SESSION 15 (cont'd):
LIVER CANCER**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
<i>Contributed Papers:</i>			
38-BRA-14	F. Riccardi, et al	Brazil	Carcinogenesis induction with diethylnitrosamine in mice: A tumor model for the evaluation of unresectable primary or metastatic liver carcinoma treatment with radioisotopes
52-COL-1	P. Bernal Trujillo, et al	Colombia	Evaluation of rhenium-188 lipiodol in the treatment of liver cancer: Experience in Colombia between 2001–2003
89-IND-11	A. Kumar, et al	India	Transarterial Re-188 labeled lipiodol therapy in cases of inoperable hepatocellular carcinoma
103-IND-25	D.K. Hazra, et al	India	Experience with an anti TPS monoclonal in radioimmunotargeting in hepatic metastases
125-MON-1	P. Onkhuudai, et al	Mongolia	Transarterial radionuclide Re-188-Lipiodol treatment of HCC
164-SIN-1	F.X. Sundram, et al	Singapore	Preliminary results of transarterial rhenium-188 HDD lipiodol in treatment of inoperable primary hepatocellular carcinoma
219-VIE-3	Trinh Thi Minh Chau, et al	Vietnam	Some preliminary experiences on treatment unoperable liver cancer with Re-188 HTDD lipiodol

15:45–16:00 Tea/Coffee Break

**16:00–17:30 SESSION 16:
INTERACTIVE SESSION**

Faculty: **H.D. Royal / A.J. McEwan / C.R. Divgi /
S.J. Goldsmith, SNM
A. Alavi, USA**

Participants: **All participants of the Symposium are
encouraged to participate and contribute
in this interactive session.**

FRIDAY, 23 JANUARY 2004

08:30–10:30 **SESSION 17:
PALLIATIVE CARE AND OTHER THERAPIES**

Chairpersons: **F. Mut Bastos, Uruguay
G. Wiseman, USA**

<i>No. of Paper IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member State/Organization</i>	<i>Title of Paper</i>
--------------------------------------	----------------	--	-----------------------

Keynote Lectures:

45-CAN-1	A.J. McEwan	SNM	Treatment of metastatic bone pain
207-USA-7	S.J. Goldsmith	SNM	Development of radiolabeled anti-PSMA monoclonal antibody for prostate cancer diagnosis and therapy
212-USA-12	F. C-L. Wong	USA	Intrathecal therapy of leptomeningeal metastases using I-131 NaI

Contributed Papers:

11-ARG-9	E.P. Parma, et al	Argentina	Retreatment with ¹⁵³ Sm EDTMP in painful skeletal metastases
65-CZR-5	M. Mosa, et al	Czech Republic	Palliative radionuclide therapy by means of samarium-153
69-EST-3	S. Nazarenko, et al <i>Presented by:</i> A. Poksi	Estonia	Bone pain palliation with ¹⁵³ Sm-EDTMP: An eight year clinical experience in North Estonia
91-IND-13	G.N. Mahapatra, et al	India	Use of strontium chloride (⁸⁹ Sr) in evaluation of painful bone metastases arising from carcinoma of prostate gland
95-IND-17	U. Pandey, et al <i>Presented by:</i> M. Venkatesh	India	Radioactive skin bandages incorporating ⁹⁰ Y, ¹⁸⁸ Re and ³² P for treatment of superficial tumors
134-PAR-2	J.A. Jara Yorg, et al	Paraguay	Palliative bone pain treatment with "Samarium EDTMP in prostate and breast cancer in Paraguay"
140-PER-5	N. Alvarado Ruiz, et al	Peru	Results after therapy of pain from bone metastases with samarium 153 in our centers in Lima, Peru

10:30–11:00 Tea/Coffee Break

11:00–13:00 **SESSION 18: CLOSING**

Chairpersons: **K.E. Britton, UK**
 M-C. Lee, WFNMB

<i>No. of Paper</i> <i>IAEA-CN-117-</i>	<i>Name(s)</i>	<i>Designating Member</i> <i>State/Organization</i>	<i>Title of Paper</i>
<i>Keynote Lectures:</i>			
205-USA-5	C.R. Divgi	SNM	Future perspectives in therapeutic nuclear oncology
208-USA-8	A. Alavi	USA	Molecular imaging with PET. Prospects for 21 st century
Highlights and Closing remarks:	O. Estrela Anselmi A.K. Padhy	Brazil IAEA	

PARTICIPATION IN IAEA SCIENTIFIC MEETINGS

Governments of Member States and those organizations whose activities are relevant to the meeting subject matter are invited to designate participants for IAEA scientific conferences and symposia. In addition, the IAEA itself usually invites a very limited number of scientists as invited speakers and only participants designated or invited in this way are entitled to present papers and take part in the discussions.

Scientists interested in participating in any of the Agency's meetings should request information from the Government authorities of their own countries, in most cases their Ministry of Foreign Affairs or national atomic energy authority.

PUBLICATIONS

Symposium Proceedings

It is intended that the full texts of oral and poster presentations will be published in a special issue of the World Journal of Nuclear Medicine and that all participants will receive a free copy of the Journal as soon as possible after the Symposium.

Other IAEA Publications

Order forms for IAEA publications are available at the Conference Desk. Publications may also be ordered from the Agency's sales agents in a large number of countries or ordered directly from the Publishing Section, International Atomic Energy Agency, P.O.Box 100, A-1400 Vienna, Austria.

Email: *sales.publications@iaea.org*

Internet:

<http://www-pub.iaea.org/MTCD/publications/publications.asp>

**RECENT AGENCY PUBLICATIONS RELATED
TO THE SUBJECT OF THE SYMPOSIUM**

- STI/PUB/1141
IAEA Quality Control Atlas for Scintillation
Camera Systems 2003
- IAEA-TECDOC-1310
Optimization of Synthesis and Quality Control
Procedures for the Preparation of 18F and 123I
Labelled Peptides for Nuclear Medicine
IAEA TECDOC Series No. 1310 2002
- STI/PUB/1117
Radiological Protection for Medical Exposure
to Ionizing Radiation Safety Guide
Safety Standards Series No. RS-G-1.5 2002
- STI/PUB/1113
Radiological Protection of Patients in Diagnostic
and Interventional Radiology, Nuclear Medicine
and Radiotherapy (Including CD-ROM)
Proceedings Series 2001
- C&S Papers Series No. 7*
Radiological Protection of Patients in Diagnostic
and Interventional Radiology, Nuclear Medicine
and Radiotherapy – Contributed Papers
(CD-ROM)
C&S Papers CD Series No. 7 2001
- IAEA-HNMI
Handbook on Care, Handling and Protection
of Nuclear Medicine Instruments 2000
- STI/PUB/996
International Basic Safety Standards for
Protection Against Ionizing Radiation and for the
Safety of Radiation Sources
Safety Series No. 115
This publication is also available in: Arabic,
Chinese, French, Russian, Spanish. 1997
- STI/PUB/973
Tomography in Nuclear Medicine
Proceedings Series 1996
- STI/PUB/786
Dynamic Functional Studies in Nuclear Medicine
in Developing Countries
(Vienna, 15–19 August 1988)
Proceedings Series 1989

STI/PUB/699

Nuclear Medicine and Related Radionuclide
Applications in Developing Countries
(Vienna, 26–30 Aug. 1985)
Proceedings Series

1986

SCIENTIFIC MEETINGS SCHEDULED BY THE IAEA

2004

International Conference on Fifty Years of Nuclear Power – the
Next Fifty Years
27 June–2 July, Moscow/Obninsk, Russian Federation

International Symposium on Quality Assurance for Analytical
Methods in Isotope Hydrology
25–27 August, Vienna, Austria

International Conference on Nuclear Information and Nuclear
Knowledge Management
6–9 September, Saclay, France

International Conference on Isotopes in Environmental Studies -
Aquatic Forum 2004 26-29 October, Monaco

International Conference on Nuclear Power in the 21st Century
October/November?, Paris, France

20th IAEA Fusion Energy Conference
1–6 November, Vilamoura, Portugal

International Symposium on the Disposal of Low-Activity,
Radioactive Waste
December?, Spain

International Conference on Topical Issues in Nuclear Safety
December, China

For information on forthcoming scientific meetings, please consult
the IAEA.org website:

<http://www-pub.iaea.org/MTCD/Meetings/Meetings.asp>